Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06650501 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Study acronym: DABI-SNAP
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre to McGill University Health Centre/Research Institute of the McGill University Health Centre Show 4 more changesShow less
    • Study sites: 1 to 3
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 5 of 9 entries
    • Publications: details revised at 7 of 7 entries
  2. Lead sponsor: Emily McDonald to McGill University Health Centre/Research Institute of the McGill University Health Centre
    • Study title shortened, about 6 words
    v6
  3. Study title expanded, about 6 wordsv5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jan 2029 to Jan 2030
    • Start date changed from estimate of Jan 2026 to Jan 15, 2026
    • Site details revised
    v4
  5. Start date: Jan 7, 2026 to Jan 2026v3
  6. Start date: Jan 7, 2025 to Jan 7, 2026
    • Eligibility criteria expanded, about 39 words
    • Site contact updated
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke prevention in atrial fibrillation, prevention or treatment of venous thromboembolism). We will randomize patients to continue their existing medication or change to another medication (dabigatran) which is approved for the original indication. Dabigatran is approved in many countries for the treatment or prevention of venous thromboembolism or preventing stroke in atrial fibrillation. Unlike the other medications listed above, dabigatran seems to have activity against S. aureus in the test tube, in animal models, and in a smaller randomized controlled trial. We wish to determine if changing to dabigatran will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119). If positive, this study will support a second RCT in people who do not currently have an indication for anticoagulation.
Trial Details
NCT Number NCT06650501
Lead Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators: University of Melbourne
Conditions
(from sponsor)		 Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection, S. Aureus Bacteremia, S. Aureus Bloodstream Infection
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov